tzd-18 and Disease-Models--Animal

tzd-18 has been researched along with Disease-Models--Animal* in 1 studies

Other Studies

1 other study(ies) available for tzd-18 and Disease-Models--Animal

Article	Year
5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARalpha/gamma agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia. Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors	2003

Article

Year

5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.

Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

A novel series of 5-aryl thiazolidine-2,4-diones based dual PPARalpha/gamma agonists was identified. A number of highly potent and orally bioavailable analogues were synthesized. Efficacy study results of some of these analogues in the db/db mice model of type 2 diabetes showed them superior to rosiglitazone in correcting hyperglycemia and hypertriglyceridemia.

Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcription Factors

2003